世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

MEAの臨床検査室開発検査（LDTs）市場-2030年までの産業動向と予測


MEA Laboratory-Developed Tests (LDTs) Market - Industry Trends and Forecast to 2030

中東・アフリカの臨床検査室開発検査（LDTs）市場は、2022年の6億1,538万ドルから2030年には10億8,771万ドルに達し、2023年から2030年の予測期間中に年平均成長率7.4%で成長すると予測される。 市場区分 欧州... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年6月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		318 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

中東・アフリカの臨床検査室開発検査（LDTs）市場は、2022年の6億1,538万ドルから2030年には10億8,771万ドルに達し、2023年から2030年の予測期間中に年平均成長率7.4%で成長すると予測される。

市場区分
欧州の臨床検査室開発検査（LDTs）市場：検査タイプ別（臨床化学・免疫学、クリティカルケア、血液学、分子診断学、微生物学、その他検査）、製品タイプ別（消耗品、分析装置・機器、アクセサリー）、サンプルタイプ別（血液、尿、組織、脳脊髄液（CSF）、その他）、治療領域別（感染症、遺伝子疾患、腫瘍・癌、自己免疫疾患、泌尿器科、婦人科、その他）、性別（男性、女性）、年齢層（老年、成人、小児）、エンドユーザー（病院ラボ、単独ラボ、診断チェーン、学術機関、臨床研究機関、専門診断センター、その他）、流通チャネル（直接入札、小売販売、第三者流通、その他）、国（サウジアラビア、南アフリカ、アラブ首長国連邦、エジプト、イスラエル、中東およびアフリカのその他） - 産業動向と2030年までの予測

中東およびアフリカの臨床検査室開発試験（LDTs）市場ダイナミクスの概要

促進要因

- 個別化医薬品の需要の増加
- 分子診断学の進歩

阻害要因

- LDTの厳しい品質管理と標準化
機会

- 精密医療と標的治療の需要の増加
市場プレーヤー
中東・アフリカの臨床検査開発試験（LDTs）市場で事業を展開する主な市場プレーヤーを以下に挙げる：
- F.ホフマン・ラ・ロシュ社
- bioMérieux, Inc.
- シスメックス・コーポレーション
- バイオメリカ社
- バイオ・ラッド・ラボラトリーズ
- アボット
- シーメンス・メディカル・ソリューションズUSA
- クエスト・ダイアグノスティックス
- QIAGEN
- ユーロフィンズサイエンティフィック
- バイオデシックス
- ホロジック社
- ガーダントヘルス
- OPKOヘルス社
- BD
- ベックマン・コールター社
- ネオジェノミクス・ラボラトリーズ
- シージーン社
- BGI
- ミラブサイエンティフィック
- 23andMe社
- アジェンディア



ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 66
1.4 CURRENCY AND PRICING 68
1.5 LIMITATIONS 68
1.6 MARKETS COVERED 68
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 TEST TYPE SEGMENT LIFELINE CURVE 80
2.8 MARKET END USER COVERAGE GRID 81
2.9 DBMR MARKET POSITION GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 88
4.1 PESTEL ANALYSIS 89
4.2 PORTER'S FIVE FORCES MODEL 90
5 INDUSTRY INSIGHTS 91
6 NUMBER OF LABS 93
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 93
6.2 NUMBER OF LABS IN EUROPE 93
7 REGULATIONS OF THE MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 95
7.1 SOUTH AFRICA 95
8 MARKET OVERVIEW 96
8.1 DRIVERS 98
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 98
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 98
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 98
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 99
8.2 RESTRAINTS 99
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 99
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 100
8.3 OPPORTUNITIES 100
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 100
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 101
8.4 CHALLENGES 101
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 101
8.4.2 COMPLEX LABORATORY PROCESSES 102
9 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 103
9.1 OVERVIEW 104
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 107
9.2.1 GLUCOSE 108
9.2.1.1 GLUCOSE CHALLENGE TEST 108
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 108
9.2.2 PROTHROMBIN 109
9.2.3 METABOLIC PANEL 109
9.2.3.1 BASIC 109
9.2.3.2 COMPREHENSIVE 109
9.2.4 LIPID PANEL 109
9.2.5 LIVER PANEL 109
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 110
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 110
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 110
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 110
9.2.6 THYROID STIMULATING HORMONE 110
9.2.7 URINALYSIS 110
9.2.7.1 RED BLOOD CELL URINE TEST 111
9.2.7.2 GLUCOSE URINE TEST 111
9.2.7.3 PROTEIN URINE TEST 111
9.2.7.4 URINE PH LEVEL 111
9.2.7.5 KETONES URINE TEST 111
9.2.7.6 BILIBURIN URINE TEST 111
9.2.7.7 URINE SPECIFIC GRAVITY TEST 112
9.2.8 OTHERS 112
9.3 CRITICAL CARE 112
9.3.1 CARBOXYHAEMOGLOBIN TEST 113
9.3.2 PH TEST 113
9.3.3 POTASSIUM TEST 113
9.3.4 SODIUM TEST 113
9.3.5 METHEMOGLOBIN TEST 113
9.3.6 LACTATE TEST 113
9.3.7 OTHERS 114
9.4 HAEMATOLOGY 114
9.4.1 COMPLETE BLOOD COUNT (CBC) 115
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 115
9.4.1.2 RED BLOOD CELL COUNT (RBC) 115
9.4.2 PLATELET COUNT 115
9.4.3 BLOOD PROTEIN TESTING 116
9.4.4 OTHERS 116
9.5 MOLECULAR DIAGNOSTIC 116
9.5.1 SAMPLE TYPE 117
9.5.1.1 BLOOD 117
9.5.1.2 URINE 117
9.5.1.3 TISSUE 117
9.5.1.4 CEREBROSPINAL FLUID (CSF) 117
9.5.1.5 OTHERS 117
9.5.2 THERAPEUTIC AREA 117
9.5.2.1 INFECTIONS 118
9.5.2.2 GENETIC DISORDERS 118
9.5.2.3 ONCOLOGY/CANCER 118
9.5.2.4 AUTOIMMUNE DISEASE 118
9.5.2.5 UROLOGY 118
9.5.2.6 GYNECOLOGY 118
9.5.2.7 OTHERS 118
9.5.3 TECHNOLOGY 119
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 119
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 119
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 119
9.5.3.4 SANGER SEQUENCING 119
9.5.3.5 MICROARRAYS 119
9.5.3.6 MASS SPECTROMETRY 120
9.5.3.7 ISOTHERMAL AMPLIFICATION 120
9.5.4 END USER 120
9.5.4.1 HOSPITAL-BASED LABS 120
9.5.4.2 STAND-ALONE LABS 120
9.5.4.3 DIAGNOSTIC CHAINS 120
9.5.4.4 ACADEMIC INSTITUTES 121
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 121
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 121
9.5.4.7 OTHERS 121
9.6 MICROBIOLOGY 121
9.6.1 MICROSCOPY 122
9.6.2 CULTURE 122
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 122
9.6.4 OTHERS 122
9.7 OTHER TEST 123
9.7.1 DRUGS OF ABUSE TESTING 124
9.7.2 HEPATITIS 124
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 124
9.7.4 MALARIA 124
9.7.5 TUBERCULOSIS 124
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 124
9.7.7 OTHERS 125
10 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 126
10.1 OVERVIEW 127
10.2 CONSUMABLES 130
10.2.1 PANELS 130
10.2.2 REAGENT AND KITS 131
10.2.3 OTHERS 131
10.3 ANALYZERS AND INSTRUMENTS 131
10.3.1 FULLY-AUTOMATED INSTRUMENTS 132
10.3.2 SEMI-AUTOMATED INSTRUMENTS 132
10.3.3 OTHERS 132
10.4 ACCESSORIES 132
11 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 134
11.1 OVERVIEW 135
11.2 BLOOD 138
11.3 URINE 138
11.4 TISSUE 139
11.5 CEREBROSPINAL FLUID (CSF) 139
11.6 OTHERS 140
12 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 142
12.1 OVERVIEW 143
12.2 INFECTIONS 146
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 147
12.2.2 CLOSTRIDIUM DIFFICILE 147
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 147
12.2.4 CARBAPENEM-RESISTANT BACTERIA 147
12.2.5 FLU 147
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 148
12.2.7 CANDIDA 148
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 148
12.2.9 MENINGITIS 148
12.2.10 GASTROINTESTINAL PANEL TESTING 148
12.2.11 CHLAMYDIA 148
12.2.12 GONORRHEA 148
12.2.13 HIV 148
12.2.14 HEPATITIS B 148
12.2.15 HEPATITIS C 148
12.2.16 OTHER INFECTIOUS DISEASES 148
12.3 GENETIC DISORDERS 149
12.3.1 NEW BORN SCREENING 149
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 150
12.3.3 OTHER GENETIC TESTING 150
12.4 ONCOLOGY/CANCER 150
12.4.1 BREAST CANCER 151
12.4.2 PROSTATE CANCER 151
12.4.3 COLORECTAL CANCER 151
12.4.4 CERVICAL CANCER 151
12.4.5 KIDNEY CANCER 151
12.4.6 LIVER CANCER 151
12.4.7 BLOOD CANCER 151
12.4.8 LUNG CANCER 152
12.4.9 OTHER CANCER 152
12.5 AUTOIMMUNE DISEASE 152
12.6 UROLOGY 152
12.7 GYNECOLOGY 153
12.8 OTHERS 154
13 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 155
13.1 OVERVIEW 156
13.2 MALE 159
13.3 FEMALE 159
14 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 161
14.1 OVERVIEW 162
14.2 GERIATRICS 165
14.3 ADULT 165
14.4 PEDIATRICS 166
15 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 167
15.1 OVERVIEW 168
15.2 HOSPITAL-BASED LABS 171
15.3 STAND –ALONE LABS 171
15.4 DIAGNOSTIC CHAINS 172
15.5 ACADEMIC INSTITUTES 173
15.6 CLINICAL RESEARCH ORGANISTAION 173
15.7 SPECIALTY DIAGNOSTIC 174
15.8 OTHERS 175
16 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 176
16.1 OVERVIEW 177
16.2 DIRECT TENDER 180
16.3 RETAIL SALES 180
16.4 THIRD PARTY DISTRIBUTORS 181
16.5 OTHERS 182
17 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 183
17.1 MIDDLE EAST AND AFRICA 184
17.1.1 SAUDI ARABIA 202
17.1.2 SOUTH AFRICA 215
17.1.3 U.A.E 228
17.1.4 EGYPT 241
17.1.5 ISRAEL 254
17.1.6 REST OF MIDDLE EAST AND AFRICA 267
18 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 268
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 268
19 COMPANY PROFILES 269
19.1 F. HOFFMANN-LA ROCHE LTD. 269
19.1.1 COMPANY SNAPSHOT 269
19.1.2 REVENUE ANALYSIS 269
19.1.3 COMPANY SHARE ANALYSIS 270
19.1.4 PRODUCT PORTFOLIO 270
19.1.5 RECENT DEVELOPMENT 270
19.2 BIOMÉRIEUX 271
19.2.1 COMPANY SNAPSHOT 271
19.2.2 REVENUE ANALYSIS 271
19.2.3 COMPANY SHARE ANALYSIS 272
19.2.4 PRODUCT PORTFOLIO 272
19.2.5 RECENT DEVELOPMENTS 272
19.3 SYSMEX CORPORATION 273
19.3.1 COMPANY SNAPSHOT 273
19.3.2 REVENUE ANALYSIS 273
19.3.3 COMPANY SHARE ANALYSIS 274
19.3.4 PRODUCT PORTFOLIO 274
19.3.5 RECENT DEVELOPMENT 274
19.4 BIOMERICA. 275
19.4.1 COMPANY SNAPSHOT 275
19.4.2 REVENUE ANALYSIS 275
19.4.3 COMPANY SHARE ANALYSIS 276
19.4.4 PRODUCT PORTFOLIO 276
19.4.5 RECENT DEVELOPMENT 276
19.5 BIO-RAD LABORATORIES, INC 277
19.5.1 COMPANY SNAPSHOT 277
19.5.2 REVENUE ANALYSIS 277
19.5.3 COMPANY SHARE ANALYSIS 278
19.5.4 PRODUCT PORTFOLIO 278
19.5.5 RECENT DEVELOPMENT 278

　

ページTOPに戻る


　

Summary

The Middle East and Africa Laboratory-Developed Tests (LDTs) Marketis expected to reach USD 1,087.71 Million by 2030 from USD 615.38 Million in 2022, growing at a CAGR of 7.4% during the forecast period of 2023 to 2030.

Market Segmentation
Europe Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics, Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Country (Saudi Arabia, South Africa, UAE, Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2030

Overview of Middle East and Africa Laboratory-Developed Tests (LDTs) Market Dynamics

Drivers

• Increasing demand for personalized medicines
• Advancements in molecular diagnostics

Restraint

• Stringent quality control and standardization for LDTs
Opportunity

• Increasing demand for precision medicine and targeted therapy
Market Players
Some of the major market players operating in the Middle East and Africa Laboratory-Developed Tests (LDTs) market are:
• F. Hoffmann-La Roche Ltd
• bioMérieux, Inc.
• Sysmex Corporation
• Biomerica, Inc.
• Bio-Rad Laboratories, Inc.
• Abbott
• Siemens Medical Solutions USA, Inc.
• Quest Diagnostics Incorporated
• QIAGEN
• Eurofins Scientific
• Biodesix.
• Hologic, Inc.
• Guardant Health
• OPKO Health, Inc.
• BD
• Beckman Coulter, Inc.
• NeoGenomics Laboratories.
• Seegene Inc.
• BGI
• Milab Scientific.
• 23andMe, Inc.
• Agendia



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 66
1.4 CURRENCY AND PRICING 68
1.5 LIMITATIONS 68
1.6 MARKETS COVERED 68
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 TEST TYPE SEGMENT LIFELINE CURVE 80
2.8 MARKET END USER COVERAGE GRID 81
2.9 DBMR MARKET POSITION GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 88
4.1 PESTEL ANALYSIS 89
4.2 PORTER'S FIVE FORCES MODEL 90
5 INDUSTRY INSIGHTS 91
6 NUMBER OF LABS 93
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 93
6.2 NUMBER OF LABS IN EUROPE 93
7 REGULATIONS OF THE MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 95
7.1 SOUTH AFRICA 95
8 MARKET OVERVIEW 96
8.1 DRIVERS 98
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 98
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 98
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 98
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 99
8.2 RESTRAINTS 99
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 99
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 100
8.3 OPPORTUNITIES 100
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 100
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 101
8.4 CHALLENGES 101
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 101
8.4.2 COMPLEX LABORATORY PROCESSES 102
9 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 103
9.1 OVERVIEW 104
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 107
9.2.1 GLUCOSE 108
9.2.1.1 GLUCOSE CHALLENGE TEST 108
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 108
9.2.2 PROTHROMBIN 109
9.2.3 METABOLIC PANEL 109
9.2.3.1 BASIC 109
9.2.3.2 COMPREHENSIVE 109
9.2.4 LIPID PANEL 109
9.2.5 LIVER PANEL 109
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 110
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 110
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 110
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 110
9.2.6 THYROID STIMULATING HORMONE 110
9.2.7 URINALYSIS 110
9.2.7.1 RED BLOOD CELL URINE TEST 111
9.2.7.2 GLUCOSE URINE TEST 111
9.2.7.3 PROTEIN URINE TEST 111
9.2.7.4 URINE PH LEVEL 111
9.2.7.5 KETONES URINE TEST 111
9.2.7.6 BILIBURIN URINE TEST 111
9.2.7.7 URINE SPECIFIC GRAVITY TEST 112
9.2.8 OTHERS 112
9.3 CRITICAL CARE 112
9.3.1 CARBOXYHAEMOGLOBIN TEST 113
9.3.2 PH TEST 113
9.3.3 POTASSIUM TEST 113
9.3.4 SODIUM TEST 113
9.3.5 METHEMOGLOBIN TEST 113
9.3.6 LACTATE TEST 113
9.3.7 OTHERS 114
9.4 HAEMATOLOGY 114
9.4.1 COMPLETE BLOOD COUNT (CBC) 115
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 115
9.4.1.2 RED BLOOD CELL COUNT (RBC) 115
9.4.2 PLATELET COUNT 115
9.4.3 BLOOD PROTEIN TESTING 116
9.4.4 OTHERS 116
9.5 MOLECULAR DIAGNOSTIC 116
9.5.1 SAMPLE TYPE 117
9.5.1.1 BLOOD 117
9.5.1.2 URINE 117
9.5.1.3 TISSUE 117
9.5.1.4 CEREBROSPINAL FLUID (CSF) 117
9.5.1.5 OTHERS 117
9.5.2 THERAPEUTIC AREA 117
9.5.2.1 INFECTIONS 118
9.5.2.2 GENETIC DISORDERS 118
9.5.2.3 ONCOLOGY/CANCER 118
9.5.2.4 AUTOIMMUNE DISEASE 118
9.5.2.5 UROLOGY 118
9.5.2.6 GYNECOLOGY 118
9.5.2.7 OTHERS 118
9.5.3 TECHNOLOGY 119
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 119
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 119
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 119
9.5.3.4 SANGER SEQUENCING 119
9.5.3.5 MICROARRAYS 119
9.5.3.6 MASS SPECTROMETRY 120
9.5.3.7 ISOTHERMAL AMPLIFICATION 120
9.5.4 END USER 120
9.5.4.1 HOSPITAL-BASED LABS 120
9.5.4.2 STAND-ALONE LABS 120
9.5.4.3 DIAGNOSTIC CHAINS 120
9.5.4.4 ACADEMIC INSTITUTES 121
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 121
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 121
9.5.4.7 OTHERS 121
9.6 MICROBIOLOGY 121
9.6.1 MICROSCOPY 122
9.6.2 CULTURE 122
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 122
9.6.4 OTHERS 122
9.7 OTHER TEST 123
9.7.1 DRUGS OF ABUSE TESTING 124
9.7.2 HEPATITIS 124
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 124
9.7.4 MALARIA 124
9.7.5 TUBERCULOSIS 124
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 124
9.7.7 OTHERS 125
10 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 126
10.1 OVERVIEW 127
10.2 CONSUMABLES 130
10.2.1 PANELS 130
10.2.2 REAGENT AND KITS 131
10.2.3 OTHERS 131
10.3 ANALYZERS AND INSTRUMENTS 131
10.3.1 FULLY-AUTOMATED INSTRUMENTS 132
10.3.2 SEMI-AUTOMATED INSTRUMENTS 132
10.3.3 OTHERS 132
10.4 ACCESSORIES 132
11 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 134
11.1 OVERVIEW 135
11.2 BLOOD 138
11.3 URINE 138
11.4 TISSUE 139
11.5 CEREBROSPINAL FLUID (CSF) 139
11.6 OTHERS 140
12 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 142
12.1 OVERVIEW 143
12.2 INFECTIONS 146
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 147
12.2.2 CLOSTRIDIUM DIFFICILE 147
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 147
12.2.4 CARBAPENEM-RESISTANT BACTERIA 147
12.2.5 FLU 147
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 148
12.2.7 CANDIDA 148
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 148
12.2.9 MENINGITIS 148
12.2.10 GASTROINTESTINAL PANEL TESTING 148
12.2.11 CHLAMYDIA 148
12.2.12 GONORRHEA 148
12.2.13 HIV 148
12.2.14 HEPATITIS B 148
12.2.15 HEPATITIS C 148
12.2.16 OTHER INFECTIOUS DISEASES 148
12.3 GENETIC DISORDERS 149
12.3.1 NEW BORN SCREENING 149
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 150
12.3.3 OTHER GENETIC TESTING 150
12.4 ONCOLOGY/CANCER 150
12.4.1 BREAST CANCER 151
12.4.2 PROSTATE CANCER 151
12.4.3 COLORECTAL CANCER 151
12.4.4 CERVICAL CANCER 151
12.4.5 KIDNEY CANCER 151
12.4.6 LIVER CANCER 151
12.4.7 BLOOD CANCER 151
12.4.8 LUNG CANCER 152
12.4.9 OTHER CANCER 152
12.5 AUTOIMMUNE DISEASE 152
12.6 UROLOGY 152
12.7 GYNECOLOGY 153
12.8 OTHERS 154
13 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 155
13.1 OVERVIEW 156
13.2 MALE 159
13.3 FEMALE 159
14 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 161
14.1 OVERVIEW 162
14.2 GERIATRICS 165
14.3 ADULT 165
14.4 PEDIATRICS 166
15 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 167
15.1 OVERVIEW 168
15.2 HOSPITAL-BASED LABS 171
15.3 STAND –ALONE LABS 171
15.4 DIAGNOSTIC CHAINS 172
15.5 ACADEMIC INSTITUTES 173
15.6 CLINICAL RESEARCH ORGANISTAION 173
15.7 SPECIALTY DIAGNOSTIC 174
15.8 OTHERS 175
16 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 176
16.1 OVERVIEW 177
16.2 DIRECT TENDER 180
16.3 RETAIL SALES 180
16.4 THIRD PARTY DISTRIBUTORS 181
16.5 OTHERS 182
17 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 183
17.1 MIDDLE EAST AND AFRICA 184
17.1.1 SAUDI ARABIA 202
17.1.2 SOUTH AFRICA 215
17.1.3 U.A.E 228
17.1.4 EGYPT 241
17.1.5 ISRAEL 254
17.1.6 REST OF MIDDLE EAST AND AFRICA 267
18 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 268
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 268
19 COMPANY PROFILES 269
19.1 F. HOFFMANN-LA ROCHE LTD. 269
19.1.1 COMPANY SNAPSHOT 269
19.1.2 REVENUE ANALYSIS 269
19.1.3 COMPANY SHARE ANALYSIS 270
19.1.4 PRODUCT PORTFOLIO 270
19.1.5 RECENT DEVELOPMENT 270
19.2 BIOMÉRIEUX 271
19.2.1 COMPANY SNAPSHOT 271
19.2.2 REVENUE ANALYSIS 271
19.2.3 COMPANY SHARE ANALYSIS 272
19.2.4 PRODUCT PORTFOLIO 272
19.2.5 RECENT DEVELOPMENTS 272
19.3 SYSMEX CORPORATION 273
19.3.1 COMPANY SNAPSHOT 273
19.3.2 REVENUE ANALYSIS 273
19.3.3 COMPANY SHARE ANALYSIS 274
19.3.4 PRODUCT PORTFOLIO 274
19.3.5 RECENT DEVELOPMENT 274
19.4 BIOMERICA. 275
19.4.1 COMPANY SNAPSHOT 275
19.4.2 REVENUE ANALYSIS 275
19.4.3 COMPANY SHARE ANALYSIS 276
19.4.4 PRODUCT PORTFOLIO 276
19.4.5 RECENT DEVELOPMENT 276
19.5 BIO-RAD LABORATORIES, INC 277
19.5.1 COMPANY SNAPSHOT 277
19.5.2 REVENUE ANALYSIS 277
19.5.3 COMPANY SHARE ANALYSIS 278
19.5.4 PRODUCT PORTFOLIO 278
19.5.5 RECENT DEVELOPMENT 278

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Data Bridge Market Research社の医療分野での最新刊レポート

本レポートと同じKEY WORD（mea）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/18　10:27

154.74 円

162.88 円

199.42 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.